BMY/Zeposia addendum—The US commercial launch of Zeposia is on hold due to the COVID-19 crisis, but this doesn’t affect BMY-R, the CELG $9/sh, which depends on the dates of FDA approvals, not on the dates of commercial launches.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”